On November 3, David H. Perlmutter, MD, delivered the Hans Popper State-of-the-Art Lecture as part of the American Association for the Study of Liver Diseases (AASLD) conference in Washington, DC.
The lecture was entitled, Alpha-1 Antitrypsin Deficiency: Novel Treatment Strategies Fifty Years After Discovery, and described the history of the disease, what we have learned about its unique clinical sequellae, and novel treatment strategies that have originated from understanding the unique pathobiology.
David H. Perlmutter, MD, is the Vira I Heinz Endowed Chair of the Department of Pediatrics at the University of Pittsburgh School of Medicine. He is Distinguished Professor of Pediatrics and Professor of Cell Biology at the University and Physician-in-Chief and Scientific Director of Children’s Hospital of Pittsburgh of UPMC.
Dr. Perlmutter has carried out basic research on alpha-1-antitrypsin deficiency for over 25 years. His work has led to many new concepts about the pathobiology of liver disease in this deficiency and has suggested several new concepts for chemoprophylaxis of chronic liver injury, hepatocellular carcinoma and emphysema in this genetic disease.
In 2010 he discovered a new pharmacological strategy that prevents liver damage in a mouse model of alpha- 1-antitrypsin deficiency and that strategy is now being tested in Phase II/III clinical trials. He has been continuously funded by NIH including 4 current investigator-initiated grants on aspects of alpha- 1-antitrypsin deficiency, a T32 fellowship training grant, and a K12 Child Health Research Center of Excellence Award for training pediatric physician scientist in the molecular basis of pediatric disease.
For more about Dr. Perlmutter’s work, please visit his profile here.